APA

Lanasa M. C., Davis P. H., Datto M., Li Z., Gockerman J. P., Moore J. O., DeCastro C. M., Friedman D. R., Diehl L. F., Rehder C., Cook H., Daugherty F. J., Matta K. M. B., Weinberg J. B. & Rizzieri D. (20120525). Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. : Leukemia & lymphoma.

Chicago

Lanasa Mark C, Davis Patricia H, Datto Michael, Li Zhiguo, Gockerman Jon P, Moore Joseph O, DeCastro Carlos M, Friedman Daphne R, Diehl Louis F, Rehder Catherine, Cook Harry, Daugherty F Joseph, Matta Karen M B, Weinberg J Brice and Rizzieri David. 20120525. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. : Leukemia & lymphoma.

Harvard

Lanasa M. C., Davis P. H., Datto M., Li Z., Gockerman J. P., Moore J. O., DeCastro C. M., Friedman D. R., Diehl L. F., Rehder C., Cook H., Daugherty F. J., Matta K. M. B., Weinberg J. B. and Rizzieri D. (20120525). Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. : Leukemia & lymphoma.

MLA

Lanasa Mark C, Davis Patricia H, Datto Michael, Li Zhiguo, Gockerman Jon P, Moore Joseph O, DeCastro Carlos M, Friedman Daphne R, Diehl Louis F, Rehder Catherine, Cook Harry, Daugherty F Joseph, Matta Karen M B, Weinberg J Brice and Rizzieri David. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. : Leukemia & lymphoma. 20120525.